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Studies performed so far on different human carcinoma cell lines, as well as numerous
case-control and epidemiological studies have given proof to the protective effects of selenium
against cancer. However, the anticancer properties of selenium are site-specific. The aim of this
work was to evaluate the cytotoxic effect of selenium against CaCo2 human colon carcinoma
cells, and SW620 lymph node metastasis of colon carcinoma cell line. Three selenium
compounds, seleno-DL-cystine (SeC), seleno-L-methionine (SeM) and sodium selenite were used.
Initial number of cells was 2×104 and the cells were incubated for 72 h with the aforementioned
Se compounds at 10, 100 and 1000 µmol Se concentrations. Cytotoxicity was measured by the
MTT cell survival assay. In the present study, decreased viabilities of both CaCo2 and SW620
cells were established following the treatment with selenite, SeC, and SeM. At 10 µmol Se levels
all three chemical forms exerted a more or less anticipated cytotoxic effect with viability decreases
ranging from 22 to 37%. However, the other two levels of 100 and 1000 µmol Se did not exhibit
an expected proportional rise in cytotoxic effect compared to 10 µmol, which warrants further
research on the reasons for increased resistance of these cells. Cell morphology also indicates that
investigated Se forms induced apoptotic cell death in both cell lines. The results confirm the
applicability of Se in the prevention and treatment of the investigated cancer sites.
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A great body of evidence for the protective role of selenium against cancer has
accumulated over the last three decades, ever since the first ecological studies have
suggested an inverse relationship between selenium concentration in soil, food, and/or
blood and cancer incidence (ALLAWAY et al., 1968; SHAMBERGER & FROST, 1969;
SCHAMBERGER & WILLIS, 1971; SCHRAUZER et al., 1977). Seleniums anticancer
properties have also been extensively investigated in numerous case-control and
epidemiological studies, most of which support the hypothesis that this microelement is
an indispensable risk factor for cancer (MCCONNELL et al., 1975; SALONEN et al., 1984;
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COMSTOCK et al., 1992; RUMI et al., 1992). Probably the most convincing
epidemiological proof to the hypothesis is the intervention trial in which total cancer
mortality in the selenium-supplemented group was 50% less than in the control group
(CLARK et al., 1996). Various selenium compounds have also been demonstrated to
inhibit chemically and virally-induced carcinogenesis, both in cell culture and in vivo
(SCHRAUZER et al., 1978; MEDINA & SHEPHERD, 1980; THOMPSON & BECCI, 1980;
MEDINA et al., 1983; MILKS et al., 1985; LIAO et al., 1988; APPEL & WOUTERSEN,
1996), as well as UVR-induced skin carcinogenesis (OVERVAD et al., 1985). The
protective effects of selenium have been established in both the initiation and promotion
phases of carcinogenesis (THOMPSON & BECCI, 1980; APPEL & WOUTERSEN, 1996).
Additionally, selenium completely inhibits cancer propagation, according to GREEDER
and MILNER (1980) who examined the effect of selenium on mice with Ehrlich ascites
tumors. Many mechanisms for the anticarcinogenic and anticancer properties of
selenium have been proposed, including its antioxidant activity through selenium
containing glutathione peroxidase (GPX), involvement in carcinogen metabolism
affecting cytochrome P-450, inhibition of certain enzymes, stimulation of apoptosis,
inhibition of protein synthesis, modulation of endocrine and immune responses, etc.
(MILNER, 1985; IP, 1986; EL-BAYOUMY, 1991). Cell culture experiments have provided
most of the current knowledge on mechanisms of the elements anticancer activity.
Some selenium compounds are genotoxic while others are not, but both groups inhibit
growth of different cell lines (LU et al., 1995; STEWART et al., 1999). The extent of the
determined cytotoxic and antiproliferative effects of selenium depends on both the
selenium chemical form and the investigated cell line. It has been observed before that
the strength of selenium's protective activity may be site-specific in humans, and the best
evidence is in relation to cancers of colon, rectum and other gastro-intestinal carcinomas
(CLARK, 1985; CLARK et al., 1996).
The aim of this study was to examine the cytotoxic effects of three different forms
of selenium in two human cancer cell lines, CaCo2 human colon carcinoma and SW620
lymph node metastasis of colon carcinoma.
1. Materials and methods
1.1. Cell lines and culture
Human colon carcinoma cells (CaCo2) and poorly differentiated cells from lymph
node metastasis of colon carcinoma (SW620) were kindly provided by Professor
Kreimir Pavelic′ (Division of Molecular Medicine, Ruder Bokovic′ Institute,
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Zagreb, Croatia), and were grown in DME medium which was supplemented with 10%
fetal bovine serum, 2 mmol L-glutamine, 100 IU ml1 penicillin and 100 mg ml1
streptomycin. The cultures were equilibrated with humidified 5% CO
2
in air at 37 °C.
The effects of the investigated forms of selenium on CaCo2 and SW620 cell
morphology were also studied by light microscopy.
1.2. Cell viability assay
The quantity of cells was determined using the tetrazolium dye (MTT) test, as
described previously by HORIUCHI and co-workers (1988). CaCo2 and SW620 cells
(2×104 cells/ml) were plated onto 96-microwell plates. The tested selenium compounds
were sodium selenite, seleno-DL-cystine (SeC), and seleno-L-methionine (SeM). They
were added to the cells at 10, 100 and 1000 µmol selenium concentrations, respectively,
24 h after plating. After 3 days of incubation, the cells were stained with 20 µl of
5 mg ml1 MTT in phosphate buffered saline for 4 h. The precipitate was solubilized
with 50 µl DMSO and the plates were read with an Elisa reader at 570 nm. All
experiments were performed at least 2 times with 6 wells for each.
1.3. Determination of DNA synthesis
DNA synthesis in CaCo2 cells was determined using 3H-thymidine incorporation
assay. Six hours before end of 3-day culturing, 3H-thymidine (25 mCi ml1) was added
to a final concentration of 1 µCi ml1. The cells were harvested onto glass wool filters
using a cell harvester and the incorporated radioactivity was measured in a scintillation
counter.
2. Results
2.1. Cytotoxicity
The results of cell viability assay are given in Table 1. The survival of both
CaCo2 and SW620 cells decreased with the increasing concentration of selenite, SeC
and SeM, respectively.
2.2. DNA synthesis
Incorporation of radioactive precursor 3H-thymidine was only monitored in
CaCo2 cells at 10 and 100 µmol selenium concentrations, and the results are given in
Table 2. A dose-dependent decrease of DNA synthesis was observed, consistent with
the results of the MTT-test.
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Table 1
Effects of selenite, selenocysteine and selenomethionine on the viability of SW620 and CaCo2 cellsa
Treatment SW620 CaCo2
None 100 100
Selenite, 10 µmol 74.5 ± 3.5 63.1 ± 2.5
Selenite, 100 µmol 59.1 ± 2.7 58.4 ± 1.7
Selenite, 1000 µmol 54.8 ± 3.9 50.2 ± 3.2
Selenocysteine, 10 µmol 63.1 ± 1.9 66.9 ± 7.9
Selenocysteine, 100 µmol 61.2 ± 0.8 62.8 ± 1.7
Selenocysteine, 1000 µmol 56.2 ± 4.8 44.9 ± 16.5
Selenomethionine, 10 µmol 68.2 ± 2.1 77.9 ± 1.7
Selenomethionine, 100 µmol 60.4 ± 3.1 64.8 ± 2.6
Selenomethionine, 1000 µmol 60.2 ± 3.6 58.2 ± 3.7
a data are mean percentages of live cells ± SD
Table 2
Effects of selenite, selenocysteine and selenomethionine on DNA
synthesis in CaCo2 cells
Treatment % Incorporation of
3H-thymidine
None 100
Selenite, 10 µmol 63.6
Selenite, 100 µmol 57.9
Selenocysteine, 10 µmol 71.7
Selenocysteine, 100 µmol 53.9
Selenomethionine, 10 µmol 68.2
Selenomethionine, 100 µmol 61.4
3. Discussion
The well-documented anticarcinogenic and antitumor action of Se cannot be fully
explained by the antioxidant activity of GPX (DAVIS et al., 1999; STEWART et al.,
1999). The link between thioredoxin reductase and anticancer activity of selenium has
not been elucidated as yet. The selenium-containing enzyme reduces thioredoxin which
stimulates cell growth and is overexpressed in cancer cells (POWIS et al., 1997;
BERGGREN et al., 1999). The cytotoxic activity of Se has been the focus of the research
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concerned with its antitumor properties. Selenium compounds exert this activity
differently and with varying efficacy. In the present study the cytotoxic effects of
selenite, SeC and SeM were established against CaCo2 and SW620 cells. At 10 µmol Se
levels all three chemical forms exerted a more or less expected cytotoxic effect with
viability decreases ranging from 22 to 37% (Table 1). However, the other two levels of
100 and 1000 µmol Se caused a minor increase in the cytotoxic effect compared to
10 µmol which is especially evident in SW620 cells. None of the forms precipitated a
50% decrease in viability after 72 h of exposure of this cell line to Se (Table 1). The
percentage of CaCo2 cell viability decrease reached 50% at 1000 µmol selenite-Se,
while the same concentration of SeC decreased the number of viable CaCo2 cells by
55%. The unexpectedly low cytotoxic effects of selenite, SeC and SeM at 100 and
1000 µmol Se in both investigated cell lines could be an indication of their adaptation to
high Se concentrations, as observed before in a relatively Se-insensitive cell line (FICO
et al., 1986). It has also been established (FEARON & VOGELSTEIN, 1990) that p53 gene
is usually mutated in colonic carcinoma cells, which disables the p53-dependent
apoptosis or programmed cell death. The absence of p53 expression produces a
dramatic increase in resistance of such cells to anticancer agents (LOWE et al., 1993).
Most other authors who investigated selenite-Se cytotoxicity on different cell
lines with a dye exclusion test reported lower concentrations of selenite required to
induce a 50% decrease in cell viability (i.e. IC
50
value). This can, in part, be explained
by study design to assess selenium cytotoxicity, implying different duration of treatment,
plating density, etc. In HL-60 human leukemia cells the viability fell to 50% of control
at 34 µmol selenite level (BATIST et al., 1986). FICO and co-workers (1986) determined
97, 52, 40, and 18% decreased viabilities in different canine mammary tumor cell lines
after 72 h of incubation with 10 µmol of Se as selenite. Selenite was also shown to be
very cytotoxic to mouse keratinocyte BALB/c MK2 cell line after 24-h incubation at
317 µM (STEWART et al., 1999). No viable cells were detected at that and higher levels.
Cell viabilities were decreased 12 and 40% in B16 murine melanoma cells at 10 and
100 µmol selenite-Se concentrations, respectively (SIWEK et al., 1994). In pB16 cells
the corresponding viability decreases were 39 and 54%.
The cytotoxicity of selenite is based on its ability to generate superoxide and
oxidative free radicals which have been shown as capable of inducing cell death
(GARBERG et al., 1988; HOCKENBERY et al., 1993; SPALLHOLZ, 1994). Selenite reacts
with glutathione (GSH), as well as other thiol-containing proteins, to give
selenodiglutathione (SDG) (i.e. corresponding selenotrisulfides; RSSeSR) (GANTHER,
1968), which is an even more potent inhibitor of cell growth in vitro than selenite itself
(FICO et al., 1986; CAFFREY & FRENKEL, 1991; LANFEAR et al., 1994). SDG is then
reduced to a selenopersulfide anion (GS-Se) which in turn redox cycles producing free
radicals. Several groups of authors observed a genotoxic effect as a result of selenite-
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induced redox cycling in different cell lines (GARBERG et al., 1988; WILSON et al.,
1992; SINHA et al., 1996; STEWART et al., 1999). It has been reported that
concentrations of 10 µmol selenite and higher induce apoptotic cell death (ZHU et al.,
1996; STEWART et al., 1997). The induction of apoptosis is attributed to the free radical
oxidative stress by the oxidation of cellular GSH (DAVIS & SPALLHOLZ, 1996), and to
the endonuclease activation (LU et al., 1994). However, some authors suggested the
involvement of a Se-binding protein in growth inhibition by selenium (WU et al., 1995),
while others propose conversion of selenite to methylated compounds which
indiscriminately bind to proteins and nucleic acids (IP & GANTHER, 1990; IP et al.,
1991; WILSON et al., 1992; IP& GANTHER, 1993).
SeC was more effective than selenite in decreasing survival of B16 cells in an
MTT-assay (SIWEK et al., 1994). At 10 and 100 µmol SeC concentrations the viabilities
of B16 cells were decreased by 22 and 87%, respectively. The amount of living pB16
cells at these SeC levels dropped by 34 and 65%, respectively. Although 10 µmol SeC
caused a stronger cytotoxic effect in both SW620 and CaCo2 cells (Table 1) than in
both B16 or pB16 cells, a significant decrease in cell viability occurred in these cells
at 100 µmol level which could not be seen in either SW620 or CaCo2 cells. A
dose-dependent response exists but the lack of a more pronounced effect of both selenite
and SeC as documented by most other researchers is difficult to explain. SeC decreased
the number of viable L1210 cells by 29% after 3 h incubation at 6.33 µmol
(MILNER& HSU, 1981), while the determined IC
50
-value for HL-60 cells was 10.5 µmol
(BATIST et al., 1986).
Similarly to selenite, SeC reacts with GSH to give selenocysteine which is then
enzymatically converted to H
2
Se by the enzyme selenocysteine lyase (DICKSON &
TAPPEL, 1969; ESAKI et al., 1982). Involvement of selenide anions (Cy-Se) is
implicated in the cytotoxicity of SeC (WHITING et al., 1980). Moreover, it has been
suggested that the prooxidant catalytic action of Se is limited to the forms which can
generate the selenide anion (R-Se) (YAN & SPALLHOLZ, 1993; SPALLHOLZ, 1994). The
established lesser cytotoxicity and genotoxicity of SeC compared with selenite is
attributed to the lower reactivity of the C-bonded selenide group of SeC (Cy-Se) than
the S-bonded selenide anion of selenopersulfide (GS-Se) from inorganic Se compounds
(SHAMBERGER, 1985). Both selenite and SeC can deplete cellular GSH levels (ANUNDI
et al., 1984; YAN et al., 1991; STEWART et al., 1997). GSH is needed for the cytotoxic
effect of selenite and SeC, since the reaction between these molecules is the first step in
the metabolic conversion of selenite and SeC to Se species which redox cycle producing
reactive free radicals and peroxides (CAFFREY & FRENKEL, 1991; YAN & SPALLHOLZ,
1993). GSH can also give significant protection against reactive oxygen species
(ARRICK& NATHAN, 1984).
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In SW620 cells, 10 µmol SeM-Se induced a 31.8% drop in cell viability which is
better than its reported activity in UACC-375 melanoma or MCF-7/S breast cancer cells
and similar to DU-145 prostate cancer cell line (REDMAN et al., 1998). The effect of
SeM in SW620 cells did not increase significantly at 100 and 1000 µmol, not reaching
50% survival decrease (Table 1). Similar pattern was observed with SeM addition to
CaCo2 cells. Most authors who investigated SeM cytotoxicity determined the IC
50
of 40
to 320 µmol (PORTER et al., 1984; KAJANDER et al., 1990; REDMAN et al., 1998). In
contrast, SeM induced only a small decrease of cell survival in B16 and pB16 cells at 10
and 100 µmol levels (around 10 and 5% for B16, and around 20% at both levels for
pB16 cells) (SIWEK et al., 1994). SeM was neither toxic to HL-60 cells up to 100 µmol
(BATIST et al., 1986) nor to BALB/c MK2 mouse keratinocyte cell line up to 3170 µmol
(STEWART et al., 1999).
SeM is metabolized via the transsulfuration mechanism to selenocysteine, and
then enzymatically to H
2
Se, as already mentioned above. Considering very similar
metabolic pathways, the consistently weaker cytotoxic effects of SeM compared to SeC
are somewhat surprising (YAN et al., 1991; SIWEK et al., 1994). In part, this can be
explained by the non-specific incorporation of SeM into proteins in place of methionine
(IP & GANTHER, 1993). On the basis of their results, STEWART and co-workers (1999)
consider SeM a relatively non-toxic and non-redoxing form of Se. REDMAN and co-
workers (1997; 1998) have shown that SeM induces cell death by apoptosis which is
independent of p53. They also suggested that depletion of polyamines by SeM leads to
an apoptotic cell death and cell cycle changes.
There were no significant differences between the effects of selenite, SeC and
SeM on cell morphology. After 24 h of treatment, the majority of cells became smaller,
round shaped, and a proportion of cells spontaneously detached from the culture flask
and floated in the medium. The apoptotic characteristics of cytoplasmic vacuolization
and chromation condensation were also observed in both cell lines after 24-h treatment
with the three forms of Se.
The measurement of the rate of DNA synthesis in the presence of the three Se
forms reveals their growth inhibitory effect on CaCo2 cells (Table 2). There is no
significant difference between selenite, SeC and SeM at 10 µmol Se level. At 100 µmol
there is a slightly stronger effect of selenite and SeC evident, in comparison with SeM
(Table 2). ABDULLAEV and GONZALEZ DE MEIJA (1996) reported similar inhibitory
effect (70% of control) on DNA synthesis in HeLa cells after 1-h treatment with
10 µmol selenite. In MOD cells, however, after 24 h of Se treatment, 10 µmol selenite
reduced DNA synthesis by more than 90% (LU et al., 1995).
In spite of the lack of a proportional drop of cell survival beyond 10 µmol Se,
which warrants further research on these cell lines, the determined cytotoxic effect of Se
supports the theory of its cancer chemopreventive activity. In addition, the levels of
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most Se compounds that are 100 or 1000 higher than the normal blood concentration
could find little use in cancer prevention or treatment because of the adverse effect on
normal cells. Previous convincing findings of Se anticancer properties have led to the
development of organoselenium compounds which have high chemopreventive activity
and low toxicity, like xyleneselenocyanate (p-XSC) (EL-BAYOUMY et al., 1995). Co-
administration of Se with other anticancer substances is another approach to bypass the
toxicity of high concentrations of Se compounds to normal cells. Combinations of
natural compounds with selenite or SeM were also found to be more effective than
either of the substances alone (ABDULLAEV & GONZALEZ DE MEJIA, 1996). IP and LISK
(1996) have focused their research on the attainment of Se cancer chemopreventive
effect with Se-eriched garlic, which has been shown to be superior to regular garlic in
the suppression of mammary cancers in an animal model (IP et al., 1992). It is obvious
that cancer prevention through Se-enriched, i.e. functional foods is the best way to
utilize its chemopreventive potency on larger populations. All three chemical forms of
Se investigated in the present work occur naturally in human nutrition, although there
are differences regarding their levels in foods and absorption. From the little data on Se
species in different foods (MUTANEN, 1986), it can be concluded that SeMet is probably
the most frequent form of Se in human nutrition. A body of work also indicates that
SeMet is more readily absorbed from the gastrointestinal tract than the other two
chemical forms (LEVANDER et al., 1983; MCADAM et al., 1985).
Studies aimed at establishing Se provision to domestic animals (GAVRILOVIC′ ,
1981; GAVRILOVIC′ & MATES′ IC′ , 1987; VULENIC et al., 1987) and humans (MANDIC′ et
al., 1995; KLAPEC et al., 1998) in eastern Croatia point to suboptimal intakes, and
deficiency diseases in domestic animals have been reported. Age-adjusted colorectal
cancer mortality for the city of Osijek in 1994 is 15.8, the corresponding data for US is
13.2 (source: www.cancermundial.com). If looked at from a perspective of Se intake,
although one should always make such comparisons with caution because of numerous
other factors affecting cancer prevalence, a higher incidence of cancer should be
expected in eastern Croatia considering three to five times higher Se intakes in the USA
(LONGNECKER et al., 1991; KLAPEC et al., 1998). Both our results and current
knowledge on Se chemopreventive activity justify finding a proper way of raising Se
provision to the population of eastern Croatia, hoping that immediate research will help
clarify the role of this microelement in cancer prevalence in the area.
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